公开(公告)号：US09568469B2

公开(公告)日：2017-02-14

申请号：US15031491

申请日：2014-10-24

申请人： TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY

发明人： Kazuhiro Shigemoto

IPC分类号： G01N33/50 ,  A61K31/436 ,  A61K45/06 ,  A61K31/198 ,  A61K31/36 ,  A61K38/18 ,  A61K38/20 ,  A61K38/00

摘要： The object of the present invention is to provide a method for screening a substance involved in a metabolic shift of skeletal muscle, and a kit for screening a substance involved in a metabolic shift of skeletal muscle.The object can be solved by a muscle stem cell or myoblast comprising at least one myosin-heavy chain fusion gene selected from the group consisting of a myosin-heavy chain I fusion gene wherein a myosin-heavy chain I gene and a fluorescent protein or photoprotein gene are fused, a myosin-heavy chain IIa fusion gene wherein a myosin-heavy chain IIa gene and a fluorescent protein or photoprotein gene are fused, a myosin-heavy chain IId/x fusion gene wherein a myosin-heavy chain IId/x gene and a fluorescent protein or photoprotein gene are fused, and a myosin-heavy chain IIb fusion gene wherein a myosin-heavy chain IIb gene and a fluorescent protein or photoprotein gene are fused.

公开(公告)号：US20220326242A1

公开(公告)日：2022-10-13

申请号：US17849248

申请日：2022-06-24

申请人： FUJIFILM Corporation ,  Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology ,  National University Corporation Tokai National Higher Education and Research System

发明人： Kyojiro KAWAKAMI ,  Yasunori FUJITA ,  Masafumi ITO ,  Kosuke MIZUTANI ,  Tomokazu ISHIKAWA

IPC分类号： G01N33/574 ,  G01N33/50 ,  G01N33/543

摘要： The present invention relates to a method of assisting the diagnosis of metastatic castration resistant prostate cancer, including measuring an amount of an extracellular vesicle having phosphatidylserine and a prostate specific membrane antigen in a biological specimen derived from a subject; and determining whether or not the subject has metastatic castration resistant prostate cancer by using, as an indicator, the amount of the extracellular vesicle having phosphatidylserine and a prostate specific membrane antigen.

公开(公告)号：US11040087B2

公开(公告)日：2021-06-22

申请号：US16324194

申请日：2017-08-18

申请人： NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY ,  TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY ,  OSAKA PREFECTURAL HOSPITAL ORGANIZATION

发明人： Tatsushi Toda ,  Kazuhiro Kobayashi ,  Motoi Kanagawa ,  Tamao Endo ,  Hiroshi Manya ,  Yoshinao Wada ,  Michiko Tajiri

IPC分类号： A61K38/45 ,  A61P21/00 ,  G01N33/68

摘要： Provided is a therapeutic agent that effectively acts on a disease associated with abnormal glycosylation of dystroglycan. Also provided is a testing method for diseases associated with abnormal glycosylation of dystroglycan. Specifically, provided is a therapeutic agent for diseases associated with abnormal glycosylation of dystroglycan, containing CDP-ribitol as an active ingredient. Ribitol-phosphate is important in the glycan structure of dystroglycan. In order for ribitol-phosphate to be incorporated into a dystroglycan glycan, a material therefor (sugar donor) is required. In the present invention, it has been found for the first time that CDP-ribitol serves as the sugar donor. It has been confirmed that the glycan of ISPD-deficient cells can be restored by administering CDP-ribitol. Thus, the present invention, which allows CDP-ribitol to be utilized for supplementation therapy, has been completed.

公开(公告)号：US20160305933A1

公开(公告)日：2016-10-20

申请号：US15031491

申请日：2014-10-24

申请人： TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY

发明人： Kazuhiro SHIGEMOTO

IPC分类号： G01N33/50 ,  A61K31/436 ,  A61K38/20 ,  A61K31/36 ,  A61K38/18 ,  A61K31/198

CPC分类号： G01N33/5061 ,  A61K31/198 ,  A61K31/36 ,  A61K31/436 ,  A61K38/00 ,  A61K38/1825 ,  A61K38/2086 ,  A61K45/06 ,  G01N33/5023 ,  G01N2500/10 ,  A61K2300/00

摘要： The object of the present invention is to provide a method for screening a substance involved in a metabolic shift of skeletal muscle, and a kit for screening a substance involved in a metabolic shift of skeletal muscle.The object can be solved by a muscle stem cell or myoblast comprising at least one myosin-heavy chain fusion gene selected from the group consisting of a myosin-heavy chain I fusion gene wherein a myosin-heavy chain I gene and a fluorescent protein or photoprotein gene are fused, a myosin-heavy chain IIa fusion gene wherein a myosin-heavy chain IIa gene and a fluorescent protein or photoprotein gene are fused, a myosin-heavy chain IId/x fusion gene wherein a myosin-heavy chain IId/x gene and a fluorescent protein or photoprotein gene are fused, and a myosin-heavy chain IIb fusion gene wherein a myosin-heavy chain IIb gene and a fluorescent protein or photoprotein gene are fused.

摘要翻译： 该目的可以通过肌肉干细胞或成肌细胞来解决，所述肌肉干细胞或成肌细胞包含至少一种选自肌球蛋白 - 重链I融合基因的肌球蛋白 - 重链融合基因，其中肌球蛋白 - 重链I基因和荧光蛋白或光蛋白 基因融合，肌球蛋白 - 重链IIa融合基因，其中肌球蛋白 - 重链IIa基因和荧光蛋白或光蛋白基因融合，肌球蛋白 - 重链IId / x融合基因，其中肌球蛋白 - 重链IId / x基因 融合荧光蛋白或光蛋白基因，将肌球蛋白 - 重链IIb基因和荧光蛋白或光蛋白基因融合的肌球蛋白 - 重链IIb融合基因。

公开(公告)号：US09618502B2

公开(公告)日：2017-04-11

申请号：US15031491

申请日：2014-10-24

申请人： TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY

发明人： Kazuhiro Shigemoto

IPC分类号： G01N33/50 ,  A61K31/436 ,  A61K45/06 ,  A61K31/198 ,  A61K31/36 ,  A61K38/18 ,  A61K38/20 ,  A61K38/00

CPC分类号： G01N33/5061 ,  A61K31/198 ,  A61K31/36 ,  A61K31/436 ,  A61K38/00 ,  A61K38/1825 ,  A61K38/2086 ,  A61K45/06 ,  G01N33/5023 ,  G01N2500/10 ,  A61K2300/00

摘要： The object of the present invention is to provide a method for screening a substance involved in a metabolic shift of skeletal muscle, and a kit for screening a substance involved in a metabolic shift of skeletal muscle.The object can be solved by a muscle stem cell or myoblast comprising at least one myosin-heavy chain fusion gene selected from the group consisting of a myosin-heavy chain I fusion gene wherein a myosin-heavy chain I gene and a fluorescent protein or photoprotein gene are fused, a myosin-heavy chain IIa fusion gene wherein a myosin-heavy chain IIa gene and a fluorescent protein or photoprotein gene are fused, a myosin-heavy chain IId/x fusion gene wherein a myosin-heavy chain IId/x gene and a fluorescent protein or photoprotein gene are fused, and a myosin-heavy chain IIb fusion gene wherein a myosin-heavy chain IIb gene and a fluorescent protein or photoprotein gene are fused.

公开(公告)号：US20160281057A1

公开(公告)日：2016-09-29

申请号：US15032446

申请日：2014-10-30

申请人： Naoki YAMASHITA ,  TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY

发明人： Naoki Yamashita ,  Kumiko Nakata ,  Ikuroh Ohsawa

IPC分类号： C12N5/076

CPC分类号： C12N5/061 ,  A61K33/00 ,  C12N2500/02

摘要： The present invention addresses the problem of providing an agent for improving sperm-motility, in particular, an agent for improving forward-sperm-motility, for use on reduced-motility sperm in male infertility treatment. Prepared is a gaseous agent for improving sperm-motility consisting of a gas that contains hydrogen molecules in the amount of 1% (v/v) or higher, for example, a gas that contains hydrogen molecules in an amount of between 45 and 55% (v/v), or a liquid agent for improving sperm-motility consisting of a liquid such as physiological saline, a culture solution, or a buffer solution containing hydrogen molecules in the amount of 1% or higher of the saturation solubility thereof, for example, a liquid in which hydrogen molecules have been dissolved by bubbling. The gaseous agent for improving sperm-motility can improve the motility of sperm by contacting hydrogen gas and either semen or a dilution thereof with each other in a gaseous phase. The liquid agent for improving sperm-motility can improve the motility of sperm when used as a washing solution or diluent for semen.

摘要翻译： 本发明解决了在男性不孕症治疗中提供用于改善精子运动性的药剂，特别是用于改善前精子运动性的药剂用于减少精子活力的问题。 制备的是用于提高精子活力的气态剂，其由含有1％（v / v）以上的氢分子的气体组成，例如含有45〜55％的氢分子的气体， （v / v）或用于提高精液运动性的液体剂，其由例如生理盐水，培养溶液或含有其饱和溶解度的1％以上的氢分子的缓冲溶液组成的液体试剂用于 例如，通过鼓泡将氢分子溶解的液体。 用于提高精子活力的气态剂可以通过在气相中将氢气和精液或其稀释液彼此接触来改善精子的运动性。 用于提高精子活力的液体剂可以提高精子在作为精液的洗涤液或稀释剂时的运动性。

公开(公告)号：US20190247450A1

公开(公告)日：2019-08-15

申请号：US16342046

申请日：2017-10-30

申请人： KABUSHIKI KAISHA YAKULT HONSHA ,  TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY

发明人： Yukitoshi AOYAGI ,  Satoshi MATSUBARA ,  Yusuke HONDA ,  Ryuta AMAMOTO ,  Koji MIYAZAKI

IPC分类号： A61K35/747 ,  A61P27/02 ,  A61P27/16

CPC分类号： A61K35/747 ,  A23L33/135 ,  A61K35/744 ,  A61P1/08 ,  A61P27/02 ,  A61P27/16

摘要： Provided is an agent or a food or drink for inhibiting the onset of overall disease. An agent for inhibiting a decrease in a disease-free rate comprises a lactic acid bacterium as an active ingredient.

公开(公告)号：US10160949B2

公开(公告)日：2018-12-25

申请号：US15032446

申请日：2014-10-30

申请人： Naoki Yamashita ,  Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology

发明人： Naoki Yamashita ,  Kumiko Nakata ,  Ikuroh Ohsawa

IPC分类号： C12N5/076 ,  A61K33/00

摘要： The present invention addresses the problem of providing an agent for improving sperm-motility, in particular, an agent for improving forward-sperm-motility, for use on reduced-motility sperm in male infertility treatment. Prepared is a gaseous agent for improving sperm-motility consisting of a gas that contains hydrogen molecules in the amount of 1% (v/v) or higher, for example, a gas that contains hydrogen molecules in an amount of between 45 and 55% (v/v), or a liquid agent for improving sperm-motility consisting of a liquid such as physiological saline, a culture solution, or a buffer solution containing hydrogen molecules in the amount of 1% or higher of the saturation solubility thereof, for example, a liquid in which hydrogen molecules have been dissolved by bubbling.

公开(公告)号：US20170306400A1

公开(公告)日：2017-10-26

申请号：US15301212

申请日：2015-04-03

申请人： TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY

发明人： Kazuhiro SHIGEMOTO

IPC分类号： C12Q1/68 ,  G01N33/573 ,  G01N33/50

CPC分类号： C12Q1/6883 ,  C12N9/12 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Y207/10001 ,  G01N33/5023 ,  G01N33/573 ,  G01N33/6893 ,  G01N2333/71 ,  G01N2500/00 ,  G01N2800/10 ,  G01N2800/52 ,  G01N2800/7042

摘要： Provided is a novel biomarker for the diagnosis of aging or amyotrophy. Provided are a method for determining the state of aging or amyotrophy, a method for determining the efficacy of therapeutic or preventive effects on aging or amyotrophy, and a method of screening for a therapeutic or preventive agent for aging or amyotrophy. The biomarker is a free MuSK protein or an mRNA for a secreted MuSK.

公开(公告)号：US20170010280A1

公开(公告)日：2017-01-12

申请号：US15111513

申请日：2015-01-14

申请人： TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY ,  KURUME UNIVERSITY

发明人： Masashi TANAKA ,  Masafumi ITO ,  Yasunori FUJITA ,  Yasutoshi KOGA

IPC分类号： G01N33/68 ,  G01N33/74 ,  C12Q1/68

CPC分类号： G01N33/6893 ,  C07K16/22 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N33/6863 ,  G01N33/6872 ,  G01N33/74 ,  G01N2333/475 ,  G01N2333/4753 ,  G01N2333/52 ,  G01N2800/00 ,  G01N2800/04

摘要： To obtain data associated with a mitochondrial disease, a method includes measuring the level of at least one protein selected from the group consisting of GDF15 (growth differentiation factor 15), HGF (hepatocyte growth factor), MIG (gamma interferon induction monokine), SCF (stem cell factor) and SCGF-β (stem cell growth factor beta) in a biological sample collected from a subject. The measured protein level is compared to that of control subjects and then it is checked whether or not there is difference between the protein level of the subject and that of control subjects.

摘要翻译： 为了获得与线粒体疾病相关的数据，一种方法包括测量至少一种选自GDF15（生长分化因子15），HGF（肝细胞生长因子），MIG（γ干扰素诱导单核因子），SCF （干细胞因子）和SCGF-β（干细胞生长因子β）在从受试者收集的生物样品中。 将测量的蛋白质水平与对照受试者进行比较，然后检查受试者的蛋白质水平与对照受试者的蛋白质水平之间是否存在差异。